Business Description
Vidac Pharma Holding Plc is a London-based company focused on creating new treatments for cancer and skin diseases. Its lead product, VDA-1102 ointment, is currently in Phase 2 clinical trials and works by targeting cancer cells while leaving healthy tissue largely unharmed. The company is also advancing two earlier-stage treatments, VDA-1102 IV and VDA-1275, both aimed at addressing solid tumors. Founded in 2021, Vidac continues to build a pipeline of therapies designed to improve outcomes for patients with serious illnesses.
